You are here: SURGERY HOME > RESEARCH > CLINICAL FUNDING

Clinical Funding

NIH Grants.

Funding listed by physician. Please click on a physician's name to view.

Kelly M. McMasters, MD, PhD

Schering-Oncology Biotech

Sunbelt Melanoma Trial

Southwestern Oncology Group

Phase III Randomized Study of Four Weeks of High Dose IFN-˙2b in Stage T3 – T4 or N1 (microscopic) Melanoma

A Randomized, Placebo-Controlled Phase III Trial of Yeast Derived GM-CSF Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients with “No Evidence of Disease” after Complete Surgical Resection of “Locally Advanced” and/or Stage IVMelanoma

AVAX

M-Vax: A Feasibility and Bio-Equivalence Study Using a DNP-Modified Autologous Melanoma Tumor Cell Vaccine as Therapy in Patients with Stage III or IV Melanoma

Comparison of M-Vax Plus Low Dose Interleukin-2 versus Placebo Vaccine plus Low-Dose Interleukin-2 Paitents with Stage IV Melanoma

John Wayne Cancer Institute

Multicenter Selective Lymphadenectomy for Melanoma Trial II: A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients with Molecular or Histopathological Evidence of Metastases in the Sentinel Node

Prospective Study of the Natural History of Subjects Who Were Entered in the MMAIT-03-001 and MMAIT-04-001 Trials and Underwent Post-Operative Therapy with BCG Plus Placebo or BCG plus Canvaxin

VICAL

A Phase III Clinical Trial to Evaluate the Safety and Efficacy of Treatment with 2 mg Intralesional Allovectin-7 Compared to DTIC or TMZ in Subjects with Recurrent Metastatic Melanoma

Veridex, LLC

Identification of Gene Markers to Differentiate Benign and Malignant Melanocytic Skin Lesions

Glen A. Franklin, MD

http://www.uoflhealthcare.org/Default.aspx?tabid=504

Novo Nordisk, Inc.

A multi-center, randomized, double-blind, parallel group, placebo controlledtrial to evaluate the efficacy and safety of activated recombinant factor VII (rFVIIa/NovoSeven®/NiaStase®) in the treatment of refractory bleeding inseverely injured trauma patients


Cadence Pharmaceuticals

A Phase III, multi-center, randomized, evaluation committee-blinded study to assess the efficacy of topical administration of omiganan 1.0% gel in preventing local catheter site infections and catheter colonization in patients undergoing central venous catheterization


Eisai Pharmaceuticals

A controlled comparison of eritoran tetrasodium and placebo in patients with severe sepsis

Susan Galandiuk, MD

http://www.priceinstitute.com/grants/trials.html
http://www.uoflhealthcare.org/Default.aspx?tabid=504

Abbott Pharmaceutical, Inc.

A 5-Year, Non-Interventional Registry Study of HUMIRA® (Adalimumab)in Patients with Moderately to Severely Active Crohn’s Disease (CD) (08.0096)

Quintiles

A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects with Moderately to SeverelyActive Ulcerative Colitis (07.0085)

Galandiuk Protocol

The Association of Gastrointestinal Disease, DNA Repair, and Host Defense Genes (361.97)

Galandiuk Protocol

Prospective open label study of a smokeless tobacco product in Crohn’s disease patients with moderately to severely active Crohn’s disease who have failed prior attempts at smoking cessation (323.06)

Pacira Pharmaceutical, Inc.

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Control Study to Evaluate the Safety and Efficacy of a Single Administration of SKY0402 for Prolonged Postoperative Analgesia in Subjects

Charles R. Scoggins, MD

American College of Surgeons Oncology Group

A Phase III Randomized Double-blind Study of Adjuvant STI571 (GleevecTM) Versus Placebo in Patients Following The Resection of Primary GastroIntestinal Stromal Tumor (GIST):

Novartis

Gastrointestinal Stromal Tumors (GIST) Registry

Neoprobe

Phase II, Single Arm, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Lymphoseek as a Lymphoid Tissue Targeting Agent in Patients with Known or Suspected Melanoma or Breast Cancer Who are Undergoing Lymph Node Mapping